Department of Medical Biotechnology, Biotechnology Center of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope Medical Center, Duarte, California.
J Cell Physiol. 2020 Oct;235(10):7567-7579. doi: 10.1002/jcp.29661. Epub 2020 Mar 11.
Transcription initiation factor 90 (TIF-90), an alternatively spliced variant of TIF-IA, differs by a 90 base pair deletion of exon 6. TIF-90 has been shown to regulate ribosomal RNA (rRNA) synthesis by interacting with polymerase I (Pol I) during the initiation of ribosomal DNA (rDNA) transcription in the nucleolus. Recently, we showed that TIF-90-mediated rRNA synthesis can play an important role in driving tumorigenesis in human colon cancer cells. Here we show that TIF-90 binds GTP at threonine 310, and that GTP binding is required for TIF-90-enhanced rRNA synthesis. Overexpression of activated AKT induces TIF-90 T310, but not a GTP-binding site (TIF-90 T310N) mutant, to translocate into the nucleolus and increase rRNA synthesis. Complementing this result, treatment with mycophenolic acid (MPA), an inhibitor of GTP production, dissociates TIF-90 from Pol I and hence abolishes AKT-increased rRNA synthesis by way of TIF-90 activation. Thus, TIF-90 requires bound GTP to fulfill its function as an enhancer of rRNA synthesis. Both TIF variants are highly expressed in colon cancer cells, and depletion of TIF-IA expression in these cells results in significant sensitivity to MPA-inhibited rRNA synthesis and reduced cell proliferation. Finally, a combination of MPA and AZD8055 (an inhibitor of both AKT and mTOR) synergistically inhibits rRNA synthesis, in vivo tumor growth, and other oncogenic activities of primary human colon cancer cells, suggesting a potential avenue for the development of therapeutic treatments by targeting the regulation of rRNA synthesis by TIF proteins.
转录起始因子 90(TIF-90)是 TIF-IA 的一种可变剪接变体,通过外显子 6 的 90 个碱基对缺失而不同。TIF-90 已被证明通过与聚合酶 I(Pol I)相互作用来调节核糖体 RNA(rRNA)的合成,从而在核仁中启动核糖体 DNA(rDNA)转录。最近,我们表明,TIF-90 介导的 rRNA 合成可以在人类结肠癌细胞的肿瘤发生中发挥重要作用。在这里,我们表明 TIF-90 在苏氨酸 310 处结合 GTP,并且 GTP 结合对于 TIF-90 增强的 rRNA 合成是必需的。过表达激活的 AKT 诱导 TIF-90 T310,但不是 GTP 结合位点(TIF-90 T310N)突变体,易位到核仁并增加 rRNA 合成。补充这一结果,用麦考酚酸(MPA)处理,一种 GTP 产生的抑制剂,使 TIF-90 从 Pol I 上解离,从而通过 TIF-90 激活来消除 AKT 增加的 rRNA 合成。因此,TIF-90 需要结合 GTP 来发挥其作为 rRNA 合成增强子的功能。两种 TIF 变体在结肠癌细胞中高度表达,并且这些细胞中 TIF-IA 表达的耗尽导致对 MPA 抑制的 rRNA 合成和细胞增殖减少的显著敏感性。最后,MPA 和 AZD8055(AKT 和 mTOR 的抑制剂)的联合抑制 rRNA 合成、体内肿瘤生长和原发性人类结肠癌细胞的其他致癌活性协同作用,表明通过靶向 TIF 蛋白调节 rRNA 合成来开发治疗方法的潜在途径。